Related Experiment Videos
Verofylline, a methylxanthine bronchodilator, in asthma
Clinical Pharmacology and Therapeutics
|December 1, 1984
Summary
Verofylline, a methylxanthine bronchodilator, showed limited effectiveness in improving lung function for asthma patients in a tolerance study. Peak activity occurred 4-6 hours post-dose, but higher doses did not improve results.
Area of Science:
- Pharmacology
- Pulmonology
- Clinical Trials
Background:
- Asthma management often involves bronchodilators.
- Methylxanthines are a class of long-acting bronchodilators.
- Verofylline is a polysubstituted methylxanthine derivative.
Purpose of the Study:
- To evaluate the tolerance and bronchodilator efficacy of verofylline in adult asthma patients.
- To determine the dose-response relationship and peak activity time of verofylline.
Main Methods:
- Double-blind, crossover study involving eight adult asthma patients.
- Oral administration of verofylline or placebo.
- Weekly measurements of lung function (Peak Expiratory Flow, Forced Vital Capacity) at 2, 4, and 6 hours post-dosing.
Main Results:
- Peak drug activity was observed between 4 and 6 hours after dosing.
- The 0.05 mg/kg dose of verofylline showed greater improvements in FEV1 and PEFR compared to placebo and higher doses.
- Increased FVC was noted up to 6 hours with the 0.15 mg/kg dose.
Conclusions:
- Verofylline demonstrated good subject tolerance at the tested doses.
- The bronchodilator effect of verofylline was not substantial at the doses investigated in this study.